News

Media:

BioWorld

“Ways to build better T cells.”

A recent piece by Mar de Miguel in BioWorld discusses the first “Spotlight on Immuno-Oncology” conference of the American Society of Gene & Cell Therapy (ASGCT) — with emphasis on MeiraGTx’s poster presentation marking the introduction of MeiraGTx’s CAR T technology, RiboCAR.

“MeiraGTx CAR T design is based on an orally available small molecule inducer that controls CAR expression to improve safety, efficacy, and durability,” writes de Miguel. “Their methodology resulted in naive T cells, which were less exhausted and more durable. . . . Unlike other modulable CARs that use chemicals for protein dimerization or viral protease, RiboCAR contains a synthetic Riboswitch ON created by Meiragtx, in which the aptamer acts as a sensor for a specific inducer. Without the inducer, CAR is undetectable and depends on an increasing dose, or it decreases after removing the small molecule inducer.”

The piece also cites extensive commentary from MeiraGTX CEO and Founder Zandy Forbes on the poster, its findings, and the significance of the innovation.

Click to access the full article (log-in may be required).

August 3, 2023

Media & Honors:

Forbes 50 > 50 Innovation List

MeiraGTx CEO and Founder Dr. Zandy Forbes

has been honored with a spot on

Forbes magazine’s 50 > 50: Innovation list

for 2023, joining a trailblazing group of

fellow leaders, entrepreneurs, and visionaries.

Click for the full feature.

August 1, 2023

Media:

The Economist

In a recent piece on the business of gene therapies, The Economist cites MeiraGTx CEO and co-founder Zandy Forbes as an innovator focused on reversing rising costs in the field.

“[T]he company has decided to bring all its development and manufacturing in-house in order to radically reduce costs,” notes the article, in reference to MeiraGTx’s unique, end-to-end, vertically integrated approach to gene therapy.

June 2023

Media:

National Public Radio (NPR)

Tech Nation with Moira Gunn

“Replacing Some Of Your DNA With New DNA That Works Better — and Stopping It At Will”

MeiraGTx CEO Zandy Forbes speaks with NPR’s Moira Gunn.

To learn about everything from our Phase 3 program in RPGR to our riboswitch gene regulation platform, listen to the interview.

November 1, 2022

Audio (59 mins)

Media:

Bloomberg Surveillance

Hosted by Francine Lacqua

“MeiraGTx CEO on Potential of Gene Therapy, Innovation”

Interview

April 7, 2022

Video (4:31)

Manufacturing

MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government, Micheál Martin

Public Event

Press Release

September 16, 2022

Clinical Pipeline: Salivary

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Clinical Program Update / Data Release

December 13, 2022

MeiraGTX at the European Society of Gene and Cell Therapy (ESGCT)

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress.

Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy.

October 4, 2022

Press Release  |  Scientific Posters

Clinical Pipeline: Ocular

X-Linked Retinitis Pigmentosa (XLRP)

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP).

Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which is actively dosing patients.

October 1, 2022

Press Release  |  Data Release

Media:

Euronews Next

“This Gene Therapy Company is Testing New Tech to ‘Switch Off’ Diabetes and Obesity With a Pill”

By Natalie Huet

Article

September 28, 2022